Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

While Church & Dwight has outperformed relative to the Dow on a YTD basis, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Arrhythmia-related mortality in patients with congenital heart disease declined overall between 1999 and 2024 despite a recent upward trend.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Church & Dwight remains a Hold as domestic volume weakness persists despite international execution and innovation efforts. International segment drives growth, with 3.6% organic sales increase, but ...

I maintain a neutral view on Church & Dwight Co. due to concerns about slowing domestic growth, which could impact its valuation multiples. Despite solid 4.2% organic sales growth in 4Q24, CHD's ...